These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. Psychedelic-assisted therapies: The past, and the need to move forward responsibly. Gardner J; Carter A; O'Brien K; Seear K Int J Drug Policy; 2019 Aug; 70():94-98. PubMed ID: 31136924 [TBL] [Abstract][Full Text] [Related]
46. Chemistry and Structure-Activity Relationships of Psychedelics. Nichols DE Curr Top Behav Neurosci; 2018; 36():1-43. PubMed ID: 28401524 [TBL] [Abstract][Full Text] [Related]
47. Psychedelics as Novel Therapeutics in Alzheimer's Disease: Rationale and Potential Mechanisms. Garcia-Romeu A; Darcy S; Jackson H; White T; Rosenberg P Curr Top Behav Neurosci; 2022; 56():287-317. PubMed ID: 34734390 [TBL] [Abstract][Full Text] [Related]
48. Can psychedelic compounds play a part in drug dependence therapy? Sessa B; Johnson MW Br J Psychiatry; 2015 Jan; 206(1):1-3. PubMed ID: 25561484 [TBL] [Abstract][Full Text] [Related]
49. Psychedelic Medicines in Major Depression: Progress and Future Challenges. Bouso JC; Ona G; Dos Santos RG; Hallak JEC Adv Exp Med Biol; 2021; 1305():515-533. PubMed ID: 33834416 [TBL] [Abstract][Full Text] [Related]
50. Psychedelics as Medicines: An Emerging New Paradigm. Nichols DE; Johnson MW; Nichols CD Clin Pharmacol Ther; 2017 Feb; 101(2):209-219. PubMed ID: 28019026 [TBL] [Abstract][Full Text] [Related]
51. Why psychiatry needs psychedelics and psychedelics need psychiatry. Sessa B J Psychoactive Drugs; 2014; 46(1):57-62. PubMed ID: 24830186 [TBL] [Abstract][Full Text] [Related]
52. Phenomenology, Structure, and Dynamic of Psychedelic States. Preller KH; Vollenweider FX Curr Top Behav Neurosci; 2018; 36():221-256. PubMed ID: 28025814 [TBL] [Abstract][Full Text] [Related]
53. Psychedelic Psychiatry: Preparing for Novel Treatments Involving Altered States of Consciousness. Holoyda B Psychiatr Serv; 2020 Dec; 71(12):1297-1299. PubMed ID: 33050796 [TBL] [Abstract][Full Text] [Related]
55. The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future. Carhart-Harris RL; Goodwin GM Neuropsychopharmacology; 2017 Oct; 42(11):2105-2113. PubMed ID: 28443617 [TBL] [Abstract][Full Text] [Related]
56. Should we be leery of being Leary? Concerns about psychedelic use by psychedelic researchers. Kious B; Schwartz Z; Lewis B J Psychopharmacol; 2023 Jan; 37(1):45-48. PubMed ID: 36377548 [TBL] [Abstract][Full Text] [Related]
57. Can pragmatic research, real-world data and digital technologies aid the development of psychedelic medicine? Carhart-Harris RL; Wagner AC; Agrawal M; Kettner H; Rosenbaum JF; Gazzaley A; Nutt DJ; Erritzoe D J Psychopharmacol; 2022 Jan; 36(1):6-11. PubMed ID: 33888025 [TBL] [Abstract][Full Text] [Related]
58. Perceived outcomes of psychedelic microdosing as self-managed therapies for mental and substance use disorders. Lea T; Amada N; Jungaberle H; Schecke H; Scherbaum N; Klein M Psychopharmacology (Berl); 2020 May; 237(5):1521-1532. PubMed ID: 32043165 [TBL] [Abstract][Full Text] [Related]
59. Psychedelic-Assisted Therapy for Social Adaptability in Autistic Adults. Danforth A Curr Top Behav Neurosci; 2022; 56():71-92. PubMed ID: 34761363 [TBL] [Abstract][Full Text] [Related]